Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics, Inc. has announced a securities purchase agreement with institutional investors, aiming to raise up to $16.5 million in gross proceeds through the sale of its common stock and warrants. The transaction, which includes an upfront payment of $4.5 million, is expected to close on or about June 12, 2026. The offering comprises 1,363,638 shares of common stock and accompanying Series A and B warrants, which provide investors with the option to purchase additional shares in the future.

Atossa Therapeutics, a clinical-stage biopharmaceutical company based in Seattle, focuses on developing innovative therapies for oncology and other areas with significant unmet medical needs. The company's lead product candidate, (Z)-endoxifen, is currently undergoing clinical trials across various settings, reflecting Atossa's commitment to addressing critical health challenges. The funds raised through this offering are intended to support the clinical development of its product candidates, as well as to provide working capital and cover general corporate expenses.

The structure of the deal includes Series A warrants, which will expire five and a half years from the date of issuance, and short-term Series B warrants, set to expire two years after issuance. The potential additional gross proceeds from the Series Warrants, if fully exercised, could amount to approximately $12 million. However, there is no assurance that these warrants will be exercised, which introduces an element of uncertainty regarding the total funds Atossa may ultimately secure from this transaction.

The biopharmaceutical sector is characterized by its high level of innovation and competition, particularly in oncology, where companies are racing to develop effective treatments for various cancers. Atossa’s focus on novel therapies positions it well within this dynamic landscape. The successful completion of this fundraising effort could enhance Atossa's ability to advance its clinical programs, thereby potentially improving its market position and attractiveness to future investors.

In summary, the $16.5 million fundraising initiative by Atossa Therapeutics underscores the ongoing need for capital in the biopharmaceutical industry, particularly for companies engaged in the development of groundbreaking therapies. As the sector continues to evolve, the ability of firms like Atossa to secure funding will be crucial for sustaining innovation and meeting the demands of an increasingly competitive marketplace. The outcomes of this offering may also influence investor sentiment towards similar biopharmaceutical ventures, reflecting broader trends in the capital markets.